By Jacob Gronholt-Pedersen and Patrick Wingrove COPENHAGEN, Nov 4 (Reuters) – Obesity drugmaker Novo Nordisk raised its 2026 outlook for the third time this year on Wednesday as quarterly sales of its
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)